Does Lymphoma Run in Families? Genetic and Other Risk Factors

Lymphoma does cluster in families, but the inherited risk is more modest than many people fear. Having a first-degree relative with non-Hodgkin lymphoma (NHL) raises your own risk by roughly 50 percent, and a family history of Hodgkin lymphoma (HL) multiplies the baseline risk by about threefold. Those numbers sound alarming until you remember that the baseline risk is quite low to begin with, so even a doubled or tripled version of a small number remains small. The fuller picture involves dozens of common gene variants, immune system function, infections, autoimmune conditions, and environmental exposures that all feed into whether lymphoma develops.

How Strong Is the Family Connection?

The best data on familial risk comes from large pooled analyses and Nordic population registries, which track millions of people over decades. A pooled study of more than 10,000 NHL cases found that people who reported a first-degree relative with NHL had about 1.5 times the odds of developing NHL themselves. The risk was also elevated if the relative had Hodgkin lymphoma or leukemia instead. Brothers of NHL patients carried a particularly high risk, with roughly 2.8 times the odds of a diagnosis.¹

A Nordic study covering five countries calculated the lifetime cumulative risk of NHL among siblings of someone with NHL at about 1.6 percent, which is 1.6 times the general population risk. For parent-child pairs, the risk increase was slightly lower, around 1.4-fold.² These are real but not dramatic numbers. A comprehensive review estimated that first-degree relatives of NHL, HL, and chronic lymphocytic leukemia (CLL) patients face roughly 1.7-fold, 3.1-fold, and 8.5-fold elevated risks, respectively, of developing the same disease.³ CLL stands out as having an unusually strong familial component compared to other lymphoma subtypes.

For Hodgkin lymphoma specifically, siblings face about a sixfold increased risk compared to the general population. That jumped even higher when researchers looked at people who had multiple affected first-degree relatives, or at same-sex twins, where the risk reached roughly 57 times baseline levels.⁴ These extreme figures reflect rare situations; for most people with one affected sibling, the absolute lifetime risk still stays in the low single digits.

What Twin Studies Tell Us

The clearest way to separate genetic from environmental risk is to compare identical twins (who share all their DNA) with fraternal twins (who share about half). A landmark Scandinavian study found that among 179 pairs of identical twins where one had Hodgkin lymphoma, 10 pairs eventually both developed the disease. Among 187 pairs of fraternal twins, not a single pair became concordant. The standardized incidence ratio for identical twins was 99, meaning nearly a hundredfold increase over what you would expect by chance.⁵

That dramatic contrast tells researchers two things. First, genes clearly play a meaningful role in Hodgkin lymphoma susceptibility. Second, the fact that fraternal twins show no excess risk despite sharing a childhood home, the same family meals, and very similar environmental exposures suggests that shared household environment alone is not what drives familial clustering. The genetic contribution appears to involve many variants of small individual effect that, when inherited together, add up to meaningful susceptibility.⁶

The Genetic Landscape

If you are picturing a single “lymphoma gene” that runs through a family, the reality is more scattered. Genome-wide association studies have identified over 60 gene variants linked to lymphoma risk across multiple subtypes, but each variant carries a small effect on its own.³ The overall model is one of many low-impact variants working together, rather than a single high-penetrance mutation like those seen in some breast cancer families.

A region of the genome that keeps showing up in lymphoma studies is the major histocompatibility complex (MHC) on chromosome 6, which encodes proteins critical for immune recognition. Variants in this region have been linked to both follicular lymphoma and Hodgkin lymphoma susceptibility.⁷ That makes biological sense: the MHC region shapes how your immune system detects and responds to threats, including abnormal cells. Small differences in those immune-surveillance genes could nudge the odds of a lymphoma taking hold.

On the rare-mutation side, certain well-known cancer predisposition genes also increase lymphoma risk. A study comparing lymphoma patients against controls found that inherited mutations in TP53 carried about a ninefold increased risk of lymphoid malignancy, while mutations in ATM and CHEK2 roughly doubled the risk.⁸ TP53 mutations in particular are associated with Li-Fraumeni syndrome, a rare inherited condition that predisposes people to many cancer types. Finding such a mutation in a lymphoma patient changes clinical management and has implications for relatives, which is why genetic counseling guidelines recommend thorough collection of personal and family cancer history.⁹

Researchers studying diffuse large B-cell lymphoma (DLBCL) have catalogued hundreds of genes that can carry somatic mutations in tumor tissue. Of those, at least 24 have also been found to carry inherited mutations in the germline DNA of DLBCL patients, making them candidate predisposition genes.¹⁰ This is an area where the science is genuinely young, and the clinical significance of most of these variants remains unclear.

Inherited Immune Disorders

Some of the starkest genetic links to lymphoma come not from lymphoma-specific gene variants but from inherited conditions that cripple the immune system. People born with primary immunodeficiencies, where the immune system never develops properly, face a dramatically elevated cancer risk. Estimates suggest that up to a quarter of people with certain severe immunodeficiencies will develop a tumor during their lifetime, predominantly B-cell lymphomas.¹¹

A systematic review of the literature identified 386 reported cases of lymphoma arising in patients with primary immunodeficiencies. T-cell deficiencies were the most common underlying condition, accounting for over half of the cases.¹² These are uncommon situations, but they illustrate a broader principle that applies across many lymphoma risk factors: anything that disrupts normal immune surveillance can open the door to uncontrolled lymphocyte growth.

Infections That Raise the Risk

Several chronic infections are established risk factors for specific lymphoma subtypes, and in some cases the genetic makeup of the host shapes how those infections behave. Epstein-Barr virus (EBV) infects most people at some point and usually causes no lasting harm, but it has been linked to roughly 1 percent of cancers worldwide, including Hodgkin lymphoma and Burkitt lymphoma.¹³ Genetic studies have identified specific variants in the immune-related region of chromosome 6 that are associated with EBV-positive Hodgkin lymphoma specifically, suggesting that some people’s immune systems are genetically less equipped to keep the virus in check.¹⁴

In the gut, the bacterium Helicobacter pylori is strongly tied to a rare type called gastric MALT lymphoma. In one study of NHL patients, H. pylori antibodies were found in 45 percent of patients, and the infection was specifically associated with primary lymphomas of the stomach.¹⁵ Hepatitis C virus (HCV) has been linked to marginal zone B-cell lymphomas arising at various body sites. One study found HCV infection in about 35 percent of non-gastric marginal zone lymphoma patients, with the virus particularly associated with tumors in the skin, salivary glands, and eye area.¹⁶ Treating the underlying infection can sometimes cause these lymphomas to regress, which underscores how directly the infection drives the disease in susceptible people.

Autoimmune Diseases and Chronic Inflammation

Autoimmune conditions create a state of chronic immune activation that appears to raise lymphoma risk independently of other factors. Rheumatoid arthritis, lupus, Sjögren’s syndrome, dermatomyositis, and celiac disease have all been consistently linked to lymphoma.¹⁷

A meta-analysis quantified these risks. People with primary Sjögren’s syndrome had roughly 19 times the general population’s risk of developing NHL. Lupus carried about a sevenfold increase, and rheumatoid arthritis about a fourfold increase.¹⁸ These are substantial multipliers, and they matter for clinical surveillance. Part of the risk may come from the immune-suppressing drugs used to treat autoimmune diseases, and part from the relentless immune stimulation itself. Disentangling those two factors has proven difficult.

Immune Suppression After Organ Transplant

People who receive organ transplants take drugs that suppress the immune system to prevent rejection, and that suppression comes at a cost. Post-transplant lymphoproliferative disorders (PTLD) range from benign overgrowth of lymphoid tissue to aggressive lymphomas. Two main drivers are the overall burden of immune-suppressing medication and the activity of EBV, which can proliferate when the immune system is held in check.¹⁹

Among liver transplant recipients, aggressive anti-rejection treatments like OKT3 and high-dose steroids were significant risk factors for developing PTLD.²⁰ This is not inherited risk in the traditional sense, but it reinforces the same theme: a functioning immune system is the single most important defense against lymphoma, and anything that weakens it, whether genetic or pharmacological, shifts the odds.

Environmental and Occupational Exposures

Pesticides have drawn the most attention as potential environmental risk factors for NHL. Farmers consistently show higher NHL rates, and case-control studies have linked several pesticide classes, including organochlorines, organophosphates, and phenoxyacetic acid herbicides, to increased risk.²¹ The evidence is less consistent in large cohort studies, however, and a Swedish population-based study found that total pesticide exposure at diagnosis was not associated with lymphoma-specific survival or overall survival.²² Pesticide exposure may contribute to lymphoma development without necessarily affecting how the disease behaves once it has started, which would explain why incidence and survival studies sometimes point in different directions.

Ionizing radiation is another exposure that gets asked about frequently. The evidence here is mixed and generally weaker than people assume. A European case-control study found no association between occupational ionizing radiation exposure and lymphoma risk overall, with no upward trend across increasing dose levels.²³ A pooled analysis of people exposed to radiation at a young age also found no significant increase in lymphoma risk per unit dose, though borderline signals emerged for NHL and CLL when doses to lymphatic tissue specifically were estimated.²⁴ A broader review concluded that if radiation does increase lymphoma risk, the effect is probably no larger than for other cancer types and appears somewhat stronger for NHL than for Hodgkin lymphoma.²⁵

Body Size, Smoking, and Other Lifestyle Factors

Lifestyle factors play a role, though the connections are sometimes counterintuitive. In a large prospective study, current smokers and recent quitters had more than double the risk of Hodgkin lymphoma compared to never-smokers. Paradoxically, current or former smokers actually had a lower risk of follicular lymphoma. Severe obesity, defined as a body mass index of 35 or higher, was associated with a modest increase in NHL risk, and taller height showed a similar small increase.²⁶ These patterns held across DLBCL and follicular lymphoma subtypes when researchers examined the impact of smoking, alcohol use, and obesity on NHL survival.²⁷

The relationship between smoking and different lymphoma subtypes probably reflects the complex ways tobacco affects the immune system. Smoking suppresses certain immune responses while inflaming others, and those opposing effects may push risk in different directions depending on which lymphocyte population a particular subtype arises from.

Sex and Racial Differences

Lymphoma is not equally distributed across populations, and the patterns offer clues about both genetic and environmental contributors. A population-based analysis found that 14 out of 16 lymphoma subtypes were significantly more common in men than in women, with the largest male predominance seen in hairy cell leukemia, mantle cell lymphoma, and Burkitt lymphoma. The one exception favoring women was primary mediastinal B-cell lymphoma.²⁸

Racial and ethnic differences are also striking. White populations carry the highest incidence for most lymphoma subtypes, particularly follicular lymphoma and hairy cell leukemia. Black populations have higher rates of plasma cell neoplasms and T-cell lymphomas. Asian populations have considerably lower rates of CLL and Hodgkin lymphoma.²⁹ These differences persist after adjusting for access to care and diagnostic practices, suggesting underlying biological variation. Geographic factors layer on top: among Hispanic populations, DLBCL incidence was higher in urban areas compared to rural areas, while among Black populations, CLL incidence followed a similar urban-rural gradient.³⁰

The Gut Microbiome as an Emerging Factor

A newer avenue of research involves the trillions of bacteria living in your gut and whether their composition influences lymphoma risk. Using a statistical technique that leverages genetic data to infer cause-and-effect relationships, researchers have identified dozens of potential causal links between specific gut microbe populations and lymphoma subtypes.³¹ A separate study using the same approach pinpointed seven specific bacterial groups, including species in the Bacteroidetes phylum and the Bacilli class, that appeared to increase lymphoma risk modestly.³²

This research is preliminary and the effect sizes are small. But the microbiome interacts with the immune system constantly, and given that immune dysregulation is the thread connecting so many lymphoma risk factors, it would not be surprising if the microbial ecosystem in the gut played at least a supporting role. Whether microbiome-targeted interventions could ever influence lymphoma risk is entirely speculative at this point.

Lymphoma Genetics Across Species

Dogs develop lymphoma at high rates, and the breed-specific patterns offer a fascinating parallel to human population differences. A European study of over 1,500 canine lymphoma cases found that Dobermans, Rottweilers, boxers, and Bernese mountain dogs all showed significant genetic predispositions to the disease. The patterns went deeper than just overall risk: boxers tended to develop T-cell lymphomas, while Rottweilers predominantly developed B-cell lymphomas.³³ Dog breeds represent closed genetic populations, which makes them powerful models for understanding how inherited variation shapes cancer susceptibility. Some of the same biological pathways involved in canine lymphoma overlap with those implicated in human disease, and comparative oncology research continues to move findings back and forth between the species.

One complication noted by the researchers was that breed-specific risks varied by country, suggesting that even within a genetically defined population, local environmental factors or breeding practices modify the risk. That same gene-environment interplay is almost certainly at work in human lymphoma as well, which is part of why isolating the purely genetic contribution has been so challenging.³⁴

Interpreting Genetic Testing and Family History

One complication in modern lymphoma genetics is distinguishing true inherited mutations from a phenomenon called clonal hematopoiesis, where blood-forming cells acquire mutations over a person’s lifetime that show up in genetic testing but were never passed down from a parent. Researchers investigating germline variants in lymphoma patients have noted that some apparent inherited TP53 mutations actually represent this kind of acquired change in blood cells, which can mimic a hereditary predisposition.³⁵ This matters because a misinterpreted result could trigger unnecessary alarm for family members or lead to surveillance recommendations that do not actually apply.

For most people, having one relative with lymphoma does not warrant genetic testing on its own. The situations where formal genetic evaluation becomes more relevant include families with multiple blood cancer diagnoses across generations, diagnoses at unusually young ages, or a known cancer predisposition syndrome in the family. If you are in that position, a genetic counselor can help distinguish between the common, low-impact variants that many people carry and the rare high-penetrance mutations that genuinely change clinical management. The field is moving quickly enough that guidelines may expand in the coming years, but for now, a detailed family history remains the most practical first step.